Through its proprietary technology platform, PPI-FIT, Sibylla predicts and targets intermediate steps in the protein folding process. The company’s small molecule drug candidates disrupt the folding ...
• Stefan Ries joins as CSO, bringing more than two decades of drug development experience in the pharmaceutical industry complemented by a background in venture capital • Elena Ardini joins as VP of R ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback